The trial enrolled 620 patients with previously untreated metastatic non-small cell lung cancer, each confirmed to have a PD-L1 tumor proportion score of at least 50 percent, a threshold that generally predicts strong responsiveness to immune checkpoint inhibitors. Patients with EGFR, ALK or ROS1 alterations were excluded, since those molecular subgroups are typically managed with targeted therapies rather than immunotherapy alone. Participants were randomized to receive either the investigational combination or pembrolizumab by itself. In the experimental arm, sacituzumab govitecan was administered at a dose of 10 mg/kg intravenously on days 1 and 8 of each cycle, alongside pembrolizumab at 200 mg on day 1 of every 21-day cycle. The study was open-label, and its dual primary endpoints were progression-free survival as assessed by blinded independent central review and overall survival.

The efficacy data revealed a pattern that has become familiar in oncology trials that miss their primary goals: encouraging numerical trends that ultimately fail the test of statistical rigor. Median progression-free survival by blinded independent central review was 11.8 months for patients receiving the combination, compared with 7.7 months for those receiving pembrolizumab alone, corresponding to a hazard ratio of 0.81 with a 95 percent confidence interval of 0.66 to 1.00 and a P value of 0.0252. Although patients on the combination lived a median of roughly four months longer without their disease progressing, the result did not cross the prespecified threshold for statistical significance that the trial design demanded.

The interim overall survival analysis was even less encouraging. Median overall survival was 21.5 months in the sacituzumab govitecan plus pembrolizumab arm versus 22.8 months with pembrolizumab alone, yielding a hazard ratio of 1.07 with a 95 percent confidence interval of 0.85 to 1.35 and a P value of 0.7155. In other words, the addition of the antibody-drug conjugate produced no survival advantage at this stage of analysis, and the point estimate actually leaned slightly in favor of monotherapy. For a field in which overall survival remains the ultimate benchmark, that finding will weigh heavily on any decision about whether the combination deserves a place in clinical practice.

Secondary measures of tumor response told a somewhat more favorable story. The confirmed objective response rate was 55.6 percent for the combination compared with 43.7 percent for pembrolizumab alone, meaning a substantially larger share of patients experienced meaningful tumor shrinkage when the antibody-drug conjugate was added. The disease control rate, reported in the study table, was 83.3 percent versus 73.1 percent, respectively. Yet the duration of those responses was nearly identical between the arms, with a median duration of response of 21.4 months for the combination and 21.3 months for pembrolizumab alone. The pattern suggests that while the combination could induce responses in more patients, it did not make the responses that occurred last any longer.

Safety findings added another layer of complexity to the interpretation. Treatment-related adverse events occurred in 93.2 percent of patients receiving the combination compared with 65.4 percent of those on pembrolizumab alone. More strikingly, grade 3 or higher treatment-related adverse events affected 55.7 percent of patients in the combination arm versus 16.5 percent in the monotherapy arm, a more than threefold increase in severe toxicity. The most common treatment-related adverse events in the combination arm included anemia, alopecia, neutropenia, diarrhea and nausea, a profile consistent with the known toxicity signature of sacituzumab govitecan. Investigators reported that the safety profile was consistent with the known profiles of the individual agents, with no new or additional toxicities observed when the two drugs were given together.

Giannis Mountzios, M.D., of the Henry Dunant Hospital Center in Athens, Greece, who presented the findings, acknowledged the tension embedded in the data. While the combination of sacituzumab govitecan and pembrolizumab produced a numerically longer progression-free survival and a higher response rate, he noted, EVOKE-03/KEYNOTE-D46 did not meet statistical significance for its primary progression-free survival endpoint, and overall survival was not significantly improved at this interim analysis. He emphasized that these findings provide important information as the field continues to evaluate treatment strategies for patients with PD-L1-high metastatic non-small cell lung cancer, framing the negative result as a contribution to knowledge rather than simply a failed experiment.

The scientific rationale behind the trial was compelling enough to justify a large Phase 3 investment. Sacituzumab govitecan links a topoisomerase I inhibitor payload to an antibody targeting TROP-2, a protein widely expressed on many epithelial cancers, including a substantial proportion of non-small cell lung tumors. The drug has already secured regulatory approvals in previously treated metastatic settings, and combining antibody-drug conjugates with immune checkpoint inhibitors has become one of the most active areas of clinical research, based on the hypothesis that chemotherapy payload-induced tumor cell death can release antigens and render tumors more visible to the immune system. Pembrolizumab, an anti-PD-1 antibody, is the established first-line standard for metastatic non-small cell lung cancer with PD-L1 tumor proportion scores of 50 percent or greater when no targetable alterations are present.

Dr. Mountzios concluded that, despite a numerical improvement in progression-free survival and a higher response rate, sacituzumab govitecan plus pembrolizumab did not meet statistical significance for progression-free survival compared with pembrolizumab monotherapy in patients with untreated PD-L1-high metastatic non-small cell lung cancer, and that overall survival also did not meet statistical significance at the interim analysis. The results leave pembrolizumab monotherapy in its longstanding position as the reference standard for this population, while raising difficult questions about whether the modest numerical gains in progression-free survival justify the substantially higher toxicity burden and the absence of any demonstrated survival benefit. For now, the trial stands as a reminder that in modern oncology, promising biology and early signals do not guarantee success when subjected to the discipline of a randomized Phase 3 test.

The International Association for the Study of Lung Cancer, founded in 1974, is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies, with a membership of more than 10,000 lung cancer specialists across all disciplines in over 100 countries. The association publishes the Journal of Thoracic Oncology and convenes the World Conference on Lung Cancer, the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, which attracts nearly 7,000 researchers, physicians and specialists from more than 100 countries each year. The conference serves as the venue where pivotal trial results such as EVOKE-03/KEYNOTE-D46 are first unveiled, shaping treatment guidelines and research agendas worldwide. As the oncology community digests these findings, attention will turn to whether further analyses, biomarker-driven subgroup explorations or alternative combination strategies can eventually translate the promise of antibody-drug conjugates into durable first-line benefits for patients with advanced lung cancer.

Subject of Research: Phase 3 testing of sacituzumab govitecan plus pembrolizumab versus pembrolizumab monotherapy as first-line treatment for PD-L1-high metastatic non-small cell lung cancer

Article Title: Sacituzumab govitecan plus pembrolizumab does not meet primary endpoints in first-line PD-L1-high metastatic NSCLC

Article References: Sacituzumab govitecan plus pembrolizumab does not meet primary endpoints in first-line PD-L1-high metastatic NSCLC. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: sacituzumab govitecan, pembrolizumab, non-small cell lung cancer, PD-L1, EVOKE-03, KEYNOTE-D46, antibody-drug conjugate, immunotherapy, progression-free survival, overall survival, Phase 3 trial, IASLC

Tarlatamab is a bispecific T-cell engager, a class of engineered antibody molecules designed to bring immune cells and tumor cells into close contact so that the immune system can attack the cancer directly. The drug binds DLL3, a protein abundantly expressed on the surface of small cell lung cancer cells but largely absent from healthy tissues, on one side, and CD3 on T cells on the other. By bridging these two cell types, tarlatamab activates the patient’s own T cells against the tumor. The therapy has already demonstrated established clinical activity in small cell lung cancer when administered intravenously, and an approved intravenous regimen of 10 milligrams every two weeks is in clinical use. What has been missing until now is evidence that the drug can be delivered in a simpler way without sacrificing efficacy or safety.

DeLLphi-308 is the first study to evaluate subcutaneous administration of tarlatamab, and the rationale for exploring this route goes well beyond convenience. Intravenous infusions deliver the full dose into the bloodstream rapidly, producing high peak serum concentrations shortly after administration. Subcutaneous injection, by contrast, allows the drug to be absorbed gradually from the injection site, producing lower peak concentrations that appear over a delayed timeframe. For a bispecific T-cell engager, this pharmacokinetic difference matters. Rapid peaks are thought to contribute to cytokine release syndrome, a systemic inflammatory reaction that is the most characteristic toxicity of this drug class and a frequent reason for hospitalization and intensive monitoring. If subcutaneous dosing flattens the concentration curve, it could potentially reduce the incidence or severity of cytokine release syndrome while delivering the same total drug exposure.

The open-label, multicenter study enrolled patients with extensive-stage small cell lung cancer whose disease had progressed or recurred after at least one platinum-based therapy, the standard first-line backbone for this disease. In the first part of the study, investigators compared subcutaneous target doses of 10 milligrams and 15 milligrams, each administered every two weeks. Pharmacokinetic analysis showed that the 15 milligram subcutaneous dose achieved serum exposures comparable to the established intravenous regimen of 10 milligrams every two weeks. On the strength of that matching exposure, the 15 milligram dose was selected as the target dose for the second part of the study, where safety and preliminary antitumor activity were assessed in a larger group of patients.

As of the March 5, 2026 data cutoff, 40 patients had received the 15 milligram subcutaneous target dose. Treatment-related adverse events occurred in 85 percent of these patients, with 10 percent experiencing a grade 3 or higher event, a rate that investigators characterized as consistent with a manageable safety profile. The most common treatment-related toxicities were injection-site reactions, seen in half of the patients, and dysgeusia, a distortion of taste reported by 45 percent. Cytokine release syndrome occurred in 38 percent of patients, and decreased appetite in 20 percent. No grade 5, or fatal, treatment-related adverse events were recorded, an important benchmark for a therapy that mobilizes the immune system against cancer.

The pattern of cytokine release syndrome observed in the study was particularly notable. Events were predominantly grade 1, the mildest category, and no patient experienced grade 3 or higher cytokine release syndrome. Equally significant, no cytokine release event required dose interruption or discontinuation of therapy. For a drug class in which cytokine release has historically dictated step-up dosing schedules, hospitalization and careful monitoring, the ability to deliver full therapeutic doses subcutaneously with predominantly mild inflammatory events represents a meaningful advance in tolerability. The investigators attribute this favorable profile at least in part to the lower, delayed peak serum concentrations achieved with subcutaneous absorption.

Early efficacy signals were also encouraging. The preliminary objective response rate in the 15 milligram group was 30 percent, meaning roughly one in three patients with previously treated extensive-stage small cell lung cancer experienced measurable tumor shrinkage. In a disease where outcomes after platinum failure have historically been poor and where effective options remain scarce, this level of activity from a more convenient route of administration is a noteworthy finding. The investigators concluded that subcutaneous tarlatamab was well tolerated and that the observed safety profile, pharmacokinetic findings and preliminary antitumor activity, together with the potential convenience of subcutaneous administration, support further investigation of this approach.

The clinical implications extend beyond the numbers. Intravenous administration of bispecific therapies typically requires infusion suites, extended clinic visits and, in many protocols, initial hospitalization to manage the risk of cytokine release during the first doses. A subcutaneous formulation that can be injected quickly, with a safety profile dominated by low-grade events, could eventually allow treatment closer to home, reduce the logistical burden on patients who often travel long distances to specialized cancer centers, and expand access to an effective immunotherapy for populations currently underserved. For patients with extensive-stage small cell lung cancer, who frequently face limited life expectancy and heavy symptom burden, every reduction in treatment inconvenience carries real weight.

Speaking about the findings, Pedro Rocha, MD, of Hospital Universitari Vall d’Hebron in Barcelona, Spain, and primary author of the study, emphasized the pharmacokinetic achievement at the heart of the results. The findings from DeLLphi-308 suggest that a 15 milligram subcutaneous tarlatamab dose can achieve serum exposures comparable to the approved 10 milligram intravenous dosing administered every two weeks while maintaining a favorable safety profile, he noted. The predominantly low-grade cytokine release events and the preliminary antitumor activity, he added, support continued investigation of this more convenient route of administration. Updated data from the latest data cutoff were scheduled to be shared in an oral presentation at the conference on September 15, offering a fuller picture of both durability of response and long-term tolerability.

The DeLLphi-308 results arrive at a moment of rapid evolution in the treatment of small cell lung cancer, a disease long defined by its aggressiveness and its tendency to relapse after initial response to chemotherapy. Bispecific T-cell engagers targeting DLL3 have emerged as one of the most promising strategies for the previously treated setting, and the present study addresses the practical question of how such therapies can best be delivered. While the findings remain preliminary, based on 40 patients at a single data cutoff, the combination of matched drug exposure, predominantly mild cytokine release syndrome, no fatal treatment-related events and a 30 percent response rate provides a solid foundation for the next phase of development. If larger studies confirm these results, subcutaneous tarlatamab could become a template for how potent immune-engaging cancer therapies are administered, pairing the biological power of bispecific antibodies with the simplicity of an injection rather than an infusion.

Subject of Research: Subcutaneous administration of the bispecific T-cell engager tarlatamab in previously treated extensive-stage small cell lung cancer

Article Title: Subcutaneous tarlatamab shows favorable safety profile and antitumor activity in extensive-stage small cell lung cancer

Article References: Subcutaneous tarlatamab shows favorable safety profile and antitumor activity in extensive-stage small cell lung cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: tarlatamab, small cell lung cancer, DeLLphi-308, bispecific T-cell engager, subcutaneous immunotherapy, cytokine release syndrome, DLL3, IASLC, WCLC 2026, pharmacokinetics, extensive-stage SCLC, cancer immunotherapy

Tarlatamab is a bispecific T-cell engager, a designed molecule that simultaneously binds DLL3, a protein abundant on small cell lung cancer cells, and CD3 on T cells, physically drawing immune effector cells into contact with tumor cells and triggering cancer cell killing. When administered at 10 mg every two weeks, the drug has previously demonstrated superior overall survival compared with chemotherapy in patients whose disease had progressed after first-line treatment, a milestone that reshaped expectations for this notoriously aggressive malignancy. The central question of DeLLphi-309 was whether less frequent administration, at higher individual doses, could deliver comparable outcomes while easing the burden of frequent clinic visits.

In the trial, adults whose small cell lung cancer had progressed or recurred after first-line platinum-based chemotherapy were randomized to one of three intravenous regimens: 10 mg every two weeks, 20 mg every three weeks, or 30 mg every four weeks, each following a 1 mg step dose designed to mitigate initial immune-related toxicity. The primary endpoint was confirmed objective response rate as assessed by blinded independent central review. No formal statistical hypotheses were prespecified, and the findings were presented descriptively, meaning the results should be interpreted as exploratory rather than definitive comparative evidence.

As of May 7, 2026, 252 patients had been randomized across the three arms. Blinded independent central review confirmed objective response rates of 40% in the every-two-week group, 31% in the every-three-week group, and 27% in the every-four-week group. Investigator-assessed response rates told a somewhat more compressed story, at 36%, 37%, and 31%, respectively, highlighting how assessment methodology can influence the apparent magnitude of differences between schedules. Median progression-free survival by blinded independent central review was 4.2 months with the established every-two-week regimen, 4.1 months with the every-three-week schedule, and 2.7 months with the every-four-week schedule.

Overall survival data, while immature, added further nuance to the picture. Six-month overall survival rates were 72% with the every-two-week regimen, 85% with the every-three-week regimen, and 69% with the every-four-week regimen. Median overall survival had not yet been reached or estimated after approximately nine months of median follow-up across the three regimens, leaving the most consequential endpoint of all still open to maturation. The apparent survival advantage in the every-three-week arm, in particular, will require longer observation before any conclusions can be drawn.

Safety findings were broadly reassuring. Treatment-emergent and treatment-related adverse event rates were similar across the three dosing regimens, and investigators identified no new or unexpected safety signals. Cytokine release syndrome, the flu-like immune activation event characteristic of T-cell engagers, occurred in 60% to 70% of patients across arms but was predominantly grade 1 or 2 in severity. Immune effector cell-associated neurotoxicity syndrome, a rarer neurological toxicity, was observed in 6% to 12% of patients. Both events were numerically somewhat more frequent in the extended-interval arms, a pattern the researchers noted but did not attribute to a clear mechanism.

Pharmacokinetic analyses offered a mechanistic explanation for why the extended schedules worked as well as they did. Steady-state trough concentrations of tarlatamab were comparable across the three dosing schedules, indicating that increasing the individual dose from 10 mg to 20 mg or 30 mg successfully compensated for the longer gap between administrations. This dose-interval symmetry reflects the drug’s pharmacokinetic behavior, in which total drug exposure over time, rather than the frequency of administration per se, appears to drive both efficacy and tolerability.

Jonathan Goldman, M.D., of the University of California Los Angeles, who presented the findings, emphasized the practical implications. The data suggest that the 20 mg every-three-week and 30 mg every-four-week regimens may offer treatment flexibility for patients with small cell lung cancer, and that alternative dosing schedules for bispecific T-cell engagers generally may achieve outcomes consistent with an established regimen. For patients, fewer clinic visits can translate into less travel, reduced time away from home, and a treatment rhythm that is easier to sustain over months of therapy.

Small cell lung cancer accounts for roughly 10 to 15 percent of lung cancers and is characterized by rapid growth and early dissemination. Although initial platinum-based chemotherapy is often effective, relapse is nearly universal, and options in the second-line setting have historically delivered modest benefit. The arrival of tarlatamab marked the first meaningful expansion of the treatment arsenal in decades, and refining how the drug is delivered could extend its reach to patients for whom biweekly dosing is impractical.

The DeLLphi-309 results arrive amid a broader reassessment of how novel immunotherapies are scheduled. As experience with bispecific antibodies accumulates across hematologic and solid malignancies, investigators are increasingly testing whether dose intensity can be traded for convenience without sacrificing efficacy. For tarlatamab, the descriptive nature of these findings means longer follow-up and additional study will be needed to confirm whether extended-interval dosing can formally match the established every-two-week standard, but for a patient population with few options and significant treatment burdens, the prospect of a three- or four-week schedule represents a meaningful step toward more humane cancer care.

Subject of Research: Extended-interval tarlatamab dosing in previously treated small cell lung cancer evaluated in the Phase 2 DeLLphi-309 trial

Article Title: Extended-interval tarlatamab dosing shows consistent activity and safety in previously treated small cell lung cancer

Article References: Extended-interval tarlatamab dosing shows consistent activity and safety in previously treated small cell lung cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: tarlatamab, small cell lung cancer, DeLLphi-309, bispecific T-cell engager, DLL3, cytokine release syndrome, ICANS, dosing schedule, IASLC, WCLC 2026, immunotherapy, progression-free survival

Local consolidative therapy has a compelling biological rationale. In patients with oligometastatic disease—a state in which cancer has spread to only a small number of distant sites—previous studies in the chemotherapy era suggested that ablating visible tumors with stereotactic radiation or surgical resection could delay progression and extend survival. The idea is straightforward: fewer tumor cells means less antigenic burden, less potential for resistant clones to emerge, and a lighter load for the immune system to police. When immune checkpoint inhibitors arrived and produced durable remissions in a subset of metastatic lung cancer patients, many investigators reasoned that combining systemic immunologic activation with local tumor eradication would be a natural and powerful next step.

Yet the clinical reality has proven more complicated. Whether local consolidative therapy retains its value in patients already receiving immune checkpoint blockade has remained genuinely uncertain, because immunotherapy itself can generate abscopal effects—regression of tumors outside the radiation field—and can control micrometastatic disease in ways chemotherapy never could. The LONESTAR trial was designed to settle the question rigorously. In this open-label, single-center, randomized Phase III study, immunotherapy-naive patients with metastatic non-small cell lung cancer first received twelve weeks of induction therapy with nivolumab plus ipilimumab, a dual checkpoint blockade regimen targeting the PD-1 and CTLA-4 pathways respectively.

Patients who completed induction without disease progression or dose-limiting toxicity were then randomized to one of two strategies. The control group simply continued nivolumab and ipilimumab. The experimental group underwent local consolidative therapy followed by continued dual immunotherapy. Consolidative treatment consisted of radiation delivered to at least one disease site, with surgical resection performed when feasible. This design directly tested whether cytoreduction of residual disease adds meaningful benefit on top of an already active systemic regimen, rather than merely asking whether the two modalities can be combined safely.

At the data cutoff of June 15, 2026, 166 patients had been randomized, with 83 assigned to each arm. Seventy-seven of these patients had oligometastatic disease at the time of randomization, making the trial one of the largest prospective examinations of consolidation in this subgroup under immunotherapy. Within the local consolidative therapy arm, 71 patients received radiation to at least one disease site and 16 underwent surgery. The execution of the trial demonstrated that the combined approach is logistically feasible in a real-world oncology setting, an important finding in its own right even though the efficacy results were disappointing.

The survival numbers told a consistent story of no benefit. In the overall randomized population, median overall survival was 52.8 months with nivolumab and ipilimumab alone compared with 43.2 months when local consolidative therapy was added, a difference that favored the control arm and did not approach statistical significance, with a hazard ratio of 1.14 and a 95 percent confidence interval of 0.75 to 1.74 and a P value of 0.54. Progression-free survival showed a numerical trend in the opposite direction, at 24.3 months with immunotherapy alone versus 31.3 months with the added consolidation, but this too fell short of significance, with a hazard ratio of 0.79, a confidence interval of 0.54 to 1.15, and a P value of 0.22.

The subgroup analysis in patients with oligometastatic disease—the very population in which consolidation was expected to shine—was equally unconvincing. Median overall survival was 75.8 months with nivolumab and ipilimumab alone compared with 42 months when local consolidative therapy was added, while median progression-free survival was 44.0 months versus 35.7 months respectively. Although these comparisons are limited by subgroup size and are not powered for definitive statistical inference, the direction of the differences offers no support for the hypothesis that ablating residual oligometastatic disease after dual checkpoint blockade extends survival. For clinicians, the message is that continuing systemic immunotherapy alone remains a reasonable and potentially preferable strategy for unselected patients.

Safety findings added a further layer of nuance. The addition of local consolidative therapy did not increase the overall incidence of grade 3 or higher adverse events, which speaks to the general tolerability of combining radiation or surgery with checkpoint inhibitors. However, pneumonitis— inflammation of lung tissue, a toxicity of particular concern in lung cancer patients who have received thoracic radiation—was numerically more frequent in the consolidation arm, occurring in 9.5 percent of patients compared with 4.9 percent of those on immunotherapy alone. Investigators also observed markedly lower absolute lymphocyte counts when systemic therapy was restarted in patients who had undergone consolidation, an observation that may reflect radiation-related effects on lymphocyte pools and could have immunologic consequences for antitumor immunity.

The immunological interpretation of these results is an active subject of discussion. One hypothesis is that effective dual checkpoint blockade already controls microscopic disease so well that eliminating visible residual tumors adds little, while the procedural burden and tissue damage of radiation or surgery may perturb the immune system without providing additional selective advantage. The observed lymphocyte depletion upon restarting therapy in the consolidation arm lends some plausibility to concerns that local treatment could transiently blunt the very immune activity on which the systemic regimen depends. Alternatively, the numerical survival differences may simply reflect chance and the play of small numbers, and longer follow-up may narrow the apparent gaps.

For now, the investigators concluded that adding local consolidative therapy after induction dual checkpoint blockade was feasible but did not improve overall or progression-free survival in an unselected metastatic non-small cell lung cancer population, including patients with oligometastatic disease. The finding does not close the door entirely on local therapy in the immunotherapy era—carefully selected patients, different radiation doses, alternative sequencing, or biomarker-driven selection may still define subgroups who benefit—but it does remove an attractive assumption from routine practice. In a field where immunotherapy has already delivered median survivals approaching and exceeding four years, LONESTAR underscores a humbling lesson: when systemic therapy works this well, the bar for proving that anything added on top improves survival is extraordinarily high.

Subject of Research: Local consolidative therapy after dual immune checkpoint blockade in metastatic non-small cell lung cancer

Article Title: Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC

Article References: Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: lung cancer, NSCLC, immunotherapy, nivolumab, ipilimumab, local consolidative therapy, LONESTAR trial, oligometastatic disease, radiation therapy, overall survival, IASLC, WCLC 2026